Evogene Ltd. reported nine-month 2026 revenues of approximately $0.8 million, down from $3.2 million in the prior year, driven by the conclusion of its Bayer agreement and lower Casterra seed sales. Despite the revenue decline, the company is advancing its aGVHD drug discovery program toward IND-enabling studies and reported that AgPlenus fungicides reduced Septoria disease severity by up to 75% in plant tissue assays.
Nine-month revenues fell to ~$0.8 million from ~$3.2 million, mainly from Casterra and the end of the Bayer agreement, while consolidated cash stood at ~$9.2 million with ~$2.4 million used in Q3, though including a one-off ~$0.5 million D&O insurance payment covering 18 months. Offsetting this, the aGVHD program reached nanomolar potency candidates heading toward IND-enabling studies and AgPlenus fungicides cut Septoria disease severity by up to 75% in plant tissue assays. Promising pipeline progress versus a shrinking revenue base and modest cash leaves the net price effect unclear.
- • Q3 2026 results published November 19, 2026
- • AgPlenus compounds reducing Septoria disease severity by up to 75% in plant tissue assays
- • Revenues down ~$2.4 million year over year to ~$0.8 million
- • Cash of ~$9.2 million with ~$2.4 million Q3 cash usage leaves a limited runway